{"entity":{"id":"tissue-factor","kind":"target","name":"Tissue factor","aka":[],"tldr":"Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.","summary":"Tissue factor (F3) initiates the extrinsic coagulation cascade; when cancers display it abnormally on their surface it drives thrombosis and angiogenesis, and it becomes an ADC target. It is overexpressed in cervical, pancreatic, head and neck, and ovarian tumours, with 90-95% of cervical and 50-80% of pancreatic cancers positive by IHC. Tisotumab vedotin (Tivdak) is approved in recurrent cervical cancer on the basis of innovaTV 301, and innovaTV did not select patients on tissue factor expression, so the drug is given without a companion test. Topoisomerase-I payload successors (XNW28012) are in phase 3. The open questions are ocular toxicity management and whether newer payloads widen the indication. The simple version is a clotting protein that cancers wear on their surface, letting an ADC find them.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Tissue_factor","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Tissue_factor"}],"tags":["adc-target"],"related":["tissue-factor-expression"],"cancers":["cervical","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["tisotumab-vedotin"],"companies":["adcendo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"F3","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Tisotumab vedotin) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA F3: RNA low tissue specificity; no normal tissue stained high; highest cancer staining skin cancer (7 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Cervical cancer, Pancreatic ductal adenocarcinoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (cervical cancer). (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas F3 tissue","url":"https://www.proteinatlas.org/ENSG00000117525-F3/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas F3 pathology","url":"https://www.proteinatlas.org/ENSG00000117525-F3/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000117525 associations","url":"https://platform.opentargets.org/target/ENSG00000117525/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3541","ensembl":"ENSG00000117525","uniprot":"P13726","entrez":"2152","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Scarpati E.M. et al, Biochemistry, 1987, \"Human tissue factor: cDNA sequence and chromosome localization of the gene\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2823875/","biology":"Initiates the extrinsic coagulation cascade; tumour expression drives thrombosis and angiogenesis.","whereFound":["Cervical","Pancreatic","Head and neck","Ovarian"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"cervical","pct":"90-95","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/Tissue_factor","note":"innovaTV did not select on TF"},{"cancerId":"pancreatic","pct":"50-80","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/Tissue_factor"}]},"route":"/targets/tissue-factor/","neighbours":{"biomarker":[{"id":"tissue-factor-expression","kind":"biomarker","name":"Tissue factor expression","route":"/biomarkers/tissue-factor-expression/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"}],"company":[{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/"},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/"}],"trial":[{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"person":[{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/"},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/"}]}}